Home About us Reports Charts News Custom Company Scan  
Report Charts News
Title Content
Life Sciences
  Metals & Minerals
Public Sector
  Finance Service
  Real Estate
Technology And Media

Tel: 0086-10-82600828
Fax: 0086-10-82601570

 The failure acquisition of Lijun Medical Equipment epitomises saturation of Chinese LargeVolume Parenteral market
CreateTime:2013-11-18 Editor:liaoyan
Text Size:       

Denied by Hongkong SEC, the acquisition deal of Lijun International Pharmaceutical from Kelun Group officially has being dropped today.

 China’s Kelun Group, Beijing Double-crane Pharmaceutical Co. and Lijun International Pharmaceutical account for over half of domestic LargeVolume Parenteral market. As the authority imposed GMP (Good Manufacturing Practice) and GSP( Good supply practice) policy, the entire medical device system is to embrace reshuffle. Also, the major medical device manufacturers face slowing growth speed. It is very obvious that the domestic LargeVolume Parenteral market is very saturated now. 

Related Reports
China Blood Product Industry Report, 2020-2027
China Medical Robot Industry Report, 2020-2026
China In Vitro Diagnostic (IVD) Industry Report, 2019-2025
China Aged Care Industry Report, 2019-2025
China Dental Industry Report, 2019-2025
2005-2021 www.researchinchina.com All Rights Reserved 京ICP备05069564号-1